Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure (BMC Nephrology, (2021), 22, 1, (391), 10.1186/s12882-021-02601-w)

Soo Kun Lim, Bak Leong Goh, Ravindran Visvanathan, Su Hyun Kim, Jin Seok Jeon, Sung Gyun Kim, Jae Hyun Chang, Chun Soo Lim, Zaki Morad

Research output: Contribution to journalComment/debate

Abstract

Following publication of the original article [1], the authors would like to correct a spelling mistake in title and in the body of the text. The word currently reads: Alpha The word should read: Alfa The title has been updated above and the original article [1] has been corrected.

Original languageEnglish
Article number14
JournalBMC nephrology
Volume23
Issue number1
DOIs
StatePublished - Dec 2022

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Fingerprint

Dive into the research topics of 'Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure (BMC Nephrology, (2021), 22, 1, (391), 10.1186/s12882-021-02601-w)'. Together they form a unique fingerprint.

Cite this